beta 2-Glycoprotein I: A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).Antibodies, Antiphospholipid: Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.Antibodies, Anticardiolipin: Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Lupus Coagulation Inhibitor: An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.Cardiolipins: Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Viral Envelope Proteins: Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.Apolipoproteins: Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Phosphatidylserines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.Interleukin-1beta: An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.Epitopes: Sites on an antigen that interact with specific antibodies.Herpesvirus 3, Human: The type species of VARICELLOVIRUS causing CHICKENPOX (varicella) and HERPES ZOSTER (shingles) in humans.Binding Sites, Antibody: Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Platelet Glycoprotein GPIb-IX Complex: Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, GPIb alpha, GPIb beta, and GPIX. Glycoprotein Ib functions as a receptor for von Willebrand factor and for thrombin. Congenital deficiency of the GPIb-IX complex results in Bernard-Soulier syndrome. The platelet glycoprotein GPV associates with GPIb-IX and is also absent in Bernard-Soulier syndrome.Immunogenetic Phenomena: GENETIC PHENOMENA characterizing IMMUNITY and the immune response.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Glycopeptides: Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight.Binding Sites: The parts of a macromolecule that directly participate in its specific combination with another molecule.beta 2-Microglobulin: An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Annexin A2: A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.OrosomucoidCells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Antigens, Heterophile: Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.Molecular Weight: The sum of the weight of all the atoms in a molecule.Myelin-Associated Glycoprotein: A myelin protein found in the periaxonal membrane of both the central and peripheral nervous systems myelin sheaths. It binds to cells surface receptors found on AXONS and may regulate cellular interactions between MYELIN and AXONS.Annexin A5: A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Platelet Membrane Glycoproteins: Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.Glycosylation: The chemical or biochemical addition of carbohydrate or glycosyl groups to other chemicals, especially peptides or proteins. Glycosyl transferases are used in this biochemical reaction.Integrin beta3: An integrin beta subunit of approximately 85-kDa in size which has been found in INTEGRIN ALPHAIIB-containing and INTEGRIN ALPHAV-containing heterodimers. Integrin beta3 occurs as three alternatively spliced isoforms, designated beta3A-C.Abortion, Habitual: Three or more consecutive spontaneous abortions.Antibody Affinity: A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.Platelet Glycoprotein GPIIb-IIIa Complex: Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.Chromatography, Affinity: A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Fibrinolysin: A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Protein Structure, Tertiary: The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Thrombin: An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.Receptors, Adrenergic, beta: One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS.Immunoglobulin Fab Fragments: Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Anticoagulants: Agents that prevent clotting.Cell Membrane: The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. (1/417)

Antiphospholipid antibodies (aPL), anti-beta 2-glycoprotein I (anti-beta 2-GPI) and anti-oxidized-low-density lipoprotein (LDL) antibodies are all implicated in the pathogenesis of antiphospholipid syndrome. To investigate whether different autoantibodies or combinations thereof produced distinct effects related to their antigenic specificities, we examined the frequencies of antiphospholipid syndrome (APS)-related features in the presence of different antibodies [aPL, beta 2-GPI, anti-oxidized low density lipoprotein (LDL)] in 125 patients with APS. Median follow-up was 72 months: 58 patients were diagnosed as primary APS and 67 as APS plus systemic lupus erythematosus (SLE). Anticardiolipin antibodies (aCL), anti-beta 2-GPI and anti-oxidized LDL antibodies were determined by ELISA; lupus anticoagulant (LA) by standard coagulometric methods. Univariate analysis showed that patients positive for anti-beta 2-GPI had a higher risk of recurrent thrombotic events (OR = 3.64, 95% CI, p = 0.01) and pregnancy loss (OR = 2.99, 95% CI, p = 0.004). Patients positive for anti-oxidized LDL antibodies had a 2.24-fold increase in the risk of arterial thrombosis (2.24, 95% CI, p = 0.03) and lower risk of thrombocytopenia (OR = 0.41 95% CI, p = 0.04). Patients positive for aCL antibodies had a higher risk of pregnancy loss (OR = 4.62 95% CI, p = 0.001). When these data were tested by multivariate logistic regression, the association between anti-beta 2-GPI and pregnancy loss and the negative association between anti-oxidized LDL antibodies and thrombocytopenia disappeared.  (+info)

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. (2/417)

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease. METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping. RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only. CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.  (+info)

Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. (3/417)

We describe the case of a 39-year-old woman who suffered two iliofemoral venous thromboses, a cerebral ischemic infarct and recurrent fetal loss. Initial studies showed high levels of antiphospholipid antibodies (APAs) and a moderate thrombocytopenia. After her second miscarriage, laboratory diagnosis revealed that the woman was heterozygous for the factor V Leiden mutation and had a functional protein S deficiency as well as anti-protein S and anti-beta 2-glycoprotein I antibodies. The impairment of the protein C pathway at various points could well explain the recurrent thromboses in the patient and supports the role of a disturbed protein C system in the pathophysiology of thrombosis in patients with APAs.  (+info)

Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. (4/417)

Cardiovascular manifestations are common in systemic lupus erythematosus (SLE). Oxidized low-density lipoprotein (oxLDL) is implicated in cardiovascular disease, especially atherosclerosis, and cross-reacts with antibodies to cardiolipin (aCL). beta 2-GPI is a plasma protein participating in the coagulating cascade, and is also cofactor for aCL, and some aCL have been shown to be directed against beta 2-GPI and/or complexes between beta 2-GPI and phospholipids. Lysophosphatidylcholine (LPC) is a phospholipid present both in oxLDL and in damaged endothelium, and we recently showed that LPC is involved in the antigenicity of oxLDL. Antibodies to endothelial cells (aEC) correlate with diseases activity in SLE and vasculitis, and we recently showed that aEC are enhanced in cardiovascular disease such as borderline hypertension and early atherosclerosis. aEC were determined using EC from adult V. Saphena Magna. Antibody levels were determined by ELISA. aEC of IgG type were enhanced in 184 patients with SLE compared with 85 healthy controls. There was a close correlation between aoxLDL, aCL, aLPC, a beta 2-GPI and aEC. Binding of sera to EC was competitively inhibited by beta 2-GPI, LPC and oxLDL. Taken together, the data indicate that EC share antigenic epitopes with beta 2-GPI and with oxLDL, especially LPC. Phospholipids in EC membranes may thus be antigenic epitopes. beta 2-GPI may bind to these phospholipids, and become an autoantigen. LPC is formed by oxidation of phospholipids and/or proinflammatory factors leading to activation of phospholipase A2, and the findings indicate the potential role of both lipid oxidation and phospholipase A2 in SLE.  (+info)

Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. (5/417)

Anti-cardiolipin autoantibodies (aCL) induce thrombosis and recurrent fetal death. These antibodies require a 'cofactor', identified as beta 2-glycoprotein I (beta 2-GPI), to bind phospholipids. We show here that aCL can bind beta 2-GPI in the absence of phospholipid. Binding of aCL to beta 2-GPI is dependent upon the beta 2-GPI being immobilized on an appropriate surface including cardiolipin, irradiated polystyrene and nitrocellulose membrane. This effect cannot be explained by increased antigen density of beta 2-GPI immobilized on these surfaces. Rather, conformational changes that occur following the interaction of beta 2-GPI with phospholipid render this protein antigenic to aCL. Liquid-phase beta 2-GPI was not antigenic for aCL. Thus, aCL cannot bind circulating beta 2-GPI. These findings may explain why patients with aCL can remain healthy for many years but then undergo episodes of thrombosis or fetal loss without changes in their circulating aCL profile, as the triggering event for these pathologies can be predicted to be one that renders beta 2-GPI antigenic for aCL.  (+info)

Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I. (6/417)

The existence of a second IgG-binding protein, protein Sbi, in Staphylococcus aureus has been reported previously. Later data indicated that protein Sbi also bound another serum component. This component has now been affinity-purified on immobilized protein Sbi and identified as beta2-glycoprotein I (beta2-GPI), also known as apolipoprotein H. The minimal beta2-GPI-binding domain was identified by shotgun phage display and the binding was shown to be mediated by a region of 57 amino acids, clearly separated from the IgG-binding domain. It is also shown that protein Sbi, and thus the beta2-GPI-binding activity, is expressed on the staphylococcal cell surface at levels varying between strains.  (+info)

Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. (7/417)

BACKGROUND: Antiphospholipid (aPL) antibodies are associated with thrombosis in patients diagnosed with antiphospholipid syndrome (APS) and enhance thrombus formation in vivo in mice, but the mechanism of thrombosis by aPL is not completely understood. Although aPL antibodies have been shown to inhibit protein C activation and activate endothelial cells (ECs) in vitro, no study has examined whether these antibodies activate ECs in vivo. Therefore, human affinity-purified aPL (ap aPL) antibodies from APS patients were tested in a mouse model of microcirculation using the cremaster muscle that allows direct microscopic examination of thrombus formation and adhesion of white blood cells (WBCs) to ECs as an indication of EC activation in vivo. Adhesion molecule expression on human umbilical vein endothelial cells (HUVECs) after aPL exposure was performed to confirm EC activation in vitro. METHODS AND RESULTS: All 6 ap aPL antibodies significantly increased the expression of VCAM-1 (2.3- to 4.4-fold), with one of the antibodies also increasing the expression of E-selectin (1.6-fold) on HUVECs in vitro. In the in vivo experiments, each ap aPL antibody except for 1 preparation increased WBC sticking (mean number of WBCs ranged from 22.7 to 50.6) compared with control (14.4), which correlated with enhanced thrombus formation (mean thrombus size ranged from 1098 to 6476 versus 594 microm2 for control). CONCLUSIONS: Activation of ECs by aPL antibodies in vivo may create a prothrombotic state on ECs, which may be the first pathophysiological event of thrombosis in APS.  (+info)

Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus. (8/417)

Antiphospholipid antibodies (aPL) are found in a variety of autoimmune diseases, and are thought to predispose to arterial and venous thrombosis. These antibodies, when investigated in different assays in vitro, activate endothelial cells and promote uptake of modified LDL to macrophages. These observations suggest that aPL can contribute to atheroma development by targeting some of the sequential steps that constitute early atherogenesis. If substantiated by large-scale clinical trials, the pro-atherogenic properties of aPL may merit screening and intervention programs in selected populations.  (+info)

Saha, N.,Kamboh, M.I.,Kelly, L.J.,Ferrell, R.E.,Tay, J.S. (1992). Apolipoprotein H (beta-2-glycoprotein I) polymorphism in Asians.. Human Biology 64 (4) : 617-621. [email protected] Repository ...
TY - JOUR. T1 - Self-interaction of soluble and surface-bound β2-glycoprotein I and its enhancement by lupus anticoagulants. AU - Hayashi, Akira. AU - Hayashi, Ayumi. AU - Matsuura, Eiji. AU - Suzuki, Koji. AU - Koike, Takao. AU - Hashimoto, Eikichi. AU - Takeya, Hiroyuki. PY - 2008/10/15. Y1 - 2008/10/15. N2 - Antiphospholipid antibodies found in antiphospholipid syndrome are autoantibodies to phospholipid-binding proteins, such as β2-glycoprotein I (β2GPI). We have previously reported that among these antibodies, the so-called lupus anticoagulants (LAs) augment β2GPI binding to the phospholipid membrane surface, which is associated with the pathological action of LAs. However, the molecular mechanisms underlying this augmentation are uncertain. Here we show that β2GPI, which is monomeric in solution, self-interacts at the interface of soluble and surface-bound molecules. In addition, this self-interaction is enhanced by LA-positive, but not LA-negative, anti-β2GPI monoclonal antibodies. ...
TY - JOUR. T1 - Restricted T-cell receptor β-chain usage by T cells autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome. AU - Yoshida, Kazue. AU - Arai, Takahide. AU - Kaburaki, Junichi. AU - Ikeda, Yasuo. AU - Kawakami, Yutaka. AU - Kuwana, Masataka. PY - 2002/4/1. Y1 - 2002/4/1. N2 - We recently identified CD4+ T cells that are autoreactive to β2-glycoprotein I (β2GPI) and that promote antiphospholipid antibody production in patients with antiphospholipid syndrome (APS). In this study, T-cell receptor (TCR) β chains of β2GPI-reactive T cells were examined in 8 β2GPI-responders, including 5 patients with APS and 3 healthy subjects, using polymerase chain reaction and single-strand conformation polymorphism (PCRSSCP) analysis combined with in vitro stimulation of peripheral blood T cells with recombinant β2GPI. The TCR Vβ segments that expanded oligoclonally after stimulation with β2GPI varied among responders, but the Vβ7 and Vβ8 segments were commonly ...
Recent advances allow us to propose antibodies targeting beta-2-glycoprotein I (β2-GPI) as the most specific antibodies associated with anti-phospholipid syndrome (APS). Therefore, there is now a crucial need for powerful biological assays to adequately monitor them. It is well established that these antibodies recognize mainly cryptic epitopes, which requires a great deal of consideration in the choice of laboratory tests to identify these antibodies. To this end, an update on the pathophysiological role of β2-GPI and a meta-analysis were conducted providing an overview of the current progress towards anti-β2-GPI detection.
Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.
Abstract: The confirmation of diagnosis of the Antiphospholipid Syndrome (APS) relies on laboratory tests. Current classification criteria for definite APS mandate the use of three "standardized" laboratory assays to detect antiphospholipid antibodies (aPL) [viz: anticardiolipin (aCL) IgG and IgM, anti-β(2) glycoprotein I (anti-β(2) GPI) antibodies IgG and IgM and/or a lupus anticoagulant (LAC)], when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although International Consensus Guidelines for the determination of LAC have been published and revised, the existence of "standardized" tests for detection of aCL and anti-β(2) GPI has remained elusive. In spite of the publication of several proposals, consensus documents and expert opinions, significant inter-assay and inter-laboratory variation in the results of both aCL and anti-β(2) GPI testing still exists, which affects the consistency of the diagnosis of APS. At the 13(th) International ...
Results The sensitivity and specificity of IgG anti-DI antibodies were comparable to those of IgG aCL and IgG anti-β2GPI antibodies, while IgG anti-DI antibody sensitivity was significantly higher than that of LA (Table 1). There was a significant agreement and association (p,0.001 for both) and a significant titre correlation (p,0.001) between IgG anti-DI and IgG aCL as well as IgG anti-β2GPI antibodies (Table 2). IgG anti-DI antibody prevalence and mean titres were significantly higher in the thrombotic than in the pregnancy morbidity PAPS patients (79.6% vs 23.5% and 823.9 CU vs 34.0 CU, p,0.001 for both). Among the conventional aPL antibody profiles, the frequency of IgG anti-DI antibodies and their titres were significantly higher in the triple positivity group (94.1%, 1162.5 CU) compared to single (15.0%, 4.1 CU) and double positivity (47.1%, 443.8 CU) ones (p,0.001 for both). Finally, the prevalence of IgG anti-DI antibodies detected by the CLIA method was not significantly different in ...
Das APOH Gen kodiert das Apolipoprotein H, welches die Brücke zwischen Lipidstoffwechsel, Koagulation und Infektabwehr schlägt. Es wurde gefunden, dass einige SNPs eine Bedeutung für die Plasmakonzentration besitzen. Damit könnten sie auch einen Effekt auf die prothombotische Wirkung insbesondere bei Patienten mit Phospholipid-Antikörpern besitzen.. ...
Apolipoprotein H (Apo H) is a single chain glycoprotein consisting of 326 amino acid residues with a molecular weight of about 50 kDa and is involved in clotting mechanisms and lipid pathways [1]. Castro and colleagues report in this journal that plasma concentrations of Apo H are strongly associated with the metabolic syndrome and cardiovascular disease in type 2 diabetic patients and could be considered as a clinical marker of cardiovascular risk. The increased Apo H concentration in these patients was due to its increased liver synthesis. Apo H is attracting interest in the field of cardiovascular disease, diabetes mellitus, haemostasis and lipidology and may provide an exciting link between them but why is this?. ...
de Laat, B.; Pengo, V.; Pabinger, I.; Musial, J.; Voskuyl, A.E.; Bultink, E.M.; Ruffatti, A.; Rozman, B.; Kveder, T.; de Moerloose, P.; Boehlen, F.; Rand, J.; Ulcova-Gallova, Z.; Mertens, K.; de Groot, P.G ...
Thank you for sharing this Blood Journal article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
Rabbit polyclonal antibody raised against a full-length human APOH protein. APOH (AAH26283.1, 1 a.a. ~ 345 a.a) full-length human protein. (H00000350-D01P) - Products - Abnova
BACKGROUND/OBJECTIVES: OxLDL-β2GPI complex has been suggested to play a role in the development of atherosclerosis and other inflammatory diseases. The aim of this study was to investigate the possible association of circulating oxLDL-β2GPI with obesity-induced inflammatory state of adipose tissue and related comorbidities as metabolic syndrome development. SUBJECTS/METHODS: Two cohorts of subjects were examined in the study. Cohort I: 36 women with wide range of BMI (17-48 kg/m2) and metabolic status (with or without metabolic syndrome (MS); Cohort II: 20 obese women undergoing a dietary intervention consisting of 1 month very low-calorie diet, and 5 months of weight-stabilization period ...
Steinkasserer, Alexander; Estaller, C.; Weiss, Elisabeth H.; Sim, Robert B. und Day, Anthony J. (1991): Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. In: Biochemical Journal, Vol. 277: S. 387-391 [PDF, 830kB] ...
Willis R, Pierangeli SS, Jaskowski TD, et al. Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. Am J Clin Pathol. 2016; 145 (6): 796-805.
Compare APOH ELISA Kits from Abcam from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
APOH Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 349 amino acids (20-345 a.a.) and having a molecular mass of 38.6kDa.
This assay is designed for the detection of IgM B2 GPI antibodies in human serum. The presence of these antibodies can aid in the diagnosis of certain...
Apolipoprotein-H Human Recombinant produced in SF9 is a glycosylated, polypeptide chain containing 326 amino acids and having a molecular mass of 38,200 Dalton (excluding glycosylation), 45kDa total mass.
Gentaur molecular products has all kinds of products like :search , EYlabs \ Unconjugated Rabbit Anti_GS_I Antibody, 2mL \ AL-2401-2 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , EYlabs \ Unconjugated Rabbit Anti_RCA_I Antibody, 2mL \ AL-2001-2 for more molecular products just contact us
Looking for online definition of beta 2 glycoprotein I in the Medical Dictionary? beta 2 glycoprotein I explanation free. What is beta 2 glycoprotein I? Meaning of beta 2 glycoprotein I medical term. What does beta 2 glycoprotein I mean?
Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is adsorbed to an oxidized polystyrene surface. Oxygen atoms were introduced on a polystyrene surface by irradiation with electron or gamma-ray radiation. X-ray photoelectron spectroscopy revealed the irradiated surfaces were oxidized to generate C-O and C = O moieties. aCL derived from either APS patients or (NZW x BXSB)F1 mice bound to beta 2-GPI coated on the irradiated plates, depending on the radiation dose. Antibody binding to beta 2-GPI on the irradiated plates was competitively inhibited by simultaneous addition of cardiolipin (CL)-coated latex beads mixed together with beta 2-GPI but were unaffected by addition of excess beta 2-GPI, CL micelles, or CL-coated latex beads alone. There was a high correlation between binding values of aCL in sera from 40 APS patients obtained by the anti-beta 2-GPI enzyme-linked ...
PURPOSE OF REVIEW: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors. RECENT FINDINGS: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance ...
Blood. 117(25), 6939-6947. Agar C, de Groot PG, Marquart JA & Meijers JCM. (2011b) Evolutionary conservation of the LPS binding site of beta2-glycoprotein I. Thromb Haemost. In press. Arad A, Proulle V, Furie RA, Furie BC & Furie B. (2011) β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 117(12), 3453-3459. Bevers EM & Galli M. (1990) Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Electron microscopy analysis of β2GPI. , 2010). Analysis of EM pictures showed that more than 99% of plasma β2GPI was in a closed conformation. These observations suggested that plasma β2GPI circulates in a circular (closed) conformation, whereas after interaction with antibodies β2GPI undergoes a major conformational change into a fishhook-like (open) structure. , 1996). When antibodies toward β2GPI were added to plasma, clotting times prolonged in a β2GPI-dependent ...
Autoimmune Diseases is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies on all aspects of autoimmunity. As a multidisciplinary journal, basic science aimed at understanding the biology and mechanism of disease will be considered, as well as articles focusing on medical treatment of autoimmune diseases.
IgG was the most frequently detected isotype in all four analyzed aPL subtypes. According to diagnostic criteria, aCL were more frequently found in patients with pAPS and sAPS than in those with SLE. Similarly, aPT were more often elevated in patients with pAPS (7/10) and sAPS (6/19) than in SLE (16/63; P , 0.05). The prevalence of anti-β2-GPI and aANXV antibodies did not differ between patient groups. Regardless of diagnosis, aPT were always detected in combination with aCL and/or anti-β2-GPI. aPT and aANXV were regularly present in the sera positive also for aCL and/or anti-β2-GPI. aANXV was detected as a single antibody in only one patient. In the pAPS group concurrent multiple aPL varieties (three or four) were significantly more frequently present than one or two types (8/10 versus 2/10; P , 0.05). Statistically significant associations of particular aPL with clinical symptoms were as follows: elevated IgG anti-β2-GPI with arterial thromboses, thrombocytopenia and foetal loss; IgG aPT ...
Results Seventy six patients with APS were included: 11 patients with primary APS, 65 patients with secondary APS. Their mean disease duration was 9.59±7.39years. The most frequent clinical manifestation from DIAPS was the peripheral vascular (deep vein thrombosis, intermittent claudication, tissue loss, vascular venous insufficiency) found in 61.8% of patients, followed by the neuropsychiatric manifestations (46.1%). The mean DIAPS score in our cohort was 4.25±3.51, not significantly different between patients with primary vs secondary APS (4.72 vs 4.16, p=0.629). Lupus anticoagulant (LA) was found in 25 patiens (32.9%), anti cardiolipin antibodies (aCL) in 49 patients (64.5%) and antibodies to β2-glycoprotein I (β2GPI) in 23 patients (30.3%). There were 36 patients known with a single positive aPL (47.4%), 27 patients (35.5%)with 2 positive aPL and only 2 patients with triple positivity. There were no significant differences regarding antibody profile between patients with primary and ...
This is a study about why some people have certain types of proteins in their blood, called anti-phospholipid antibodies. The presence of these antibodies and associated complications (e.g. blood clots) are known to change over time. The purpose of this study is to evaluate these changes and improve our ability to determine the long-term outcome of affected individuals ...
Importantly, the high resolution inherent in CE allows complex mixtures and binding resulting in only small migration changes to be characterized quantitatively. One specific problem, however, that may be encountered when applying CE for the analysis of binding interactions of proteins is the need to avoid interactions other than those between the analyte and the ligand. Thus, protein-wall interactions in unmodified fused-silica capillaries used at neutral pH often invalidate analyses of protein binding. This problem is especially pronounced with basic proteins and proteins containing exposed patches of positive charge. In the development of suitable conditions for analysis at neutral pH of b2gpI we found the pH hysteresis behavior of fused silica surfaces useful since the protonated surface after an acid pre-wash counteracted protein adsorption efficiently in contrast to more laborious procedures including acrylamide/dimethylacrylamide coatings that did not permit analysis of this particular ...
Beta-2 glycoprotein 1 (beta-2 GP1, also called apolipoprotein H) is a 326-amino acid polypeptide synthesized by hepatocytes, endothelial cells, and trophoblast cells. It contains 5 homologous domains of approximately 60 amino acids each.(1,2) Domain 5, located at the C terminus, contains a hydrophobic core surrounded by 14 positively charged amino acid residues that promote electrostatic interactions with plasma membranes via interactions with negatively charged phospholipids. Complexes of beta-2 GP1 and phospholipids in vivo reveal epitopes that react with natural autoantibodies.(3) Plasma from normal individuals contains low concentrations of IgG autoantibodies to beta-2 GP1 (beta-2 GP1 antibodies) that are of moderate affinity and react with an epitope on the first domain near the N terminus.. Pathologic levels of beta-2 GP1 antibodies occur in patients with antiphospholipid syndrome (APS). APS is associated with a variety of clinical symptoms, notably, thrombosis, pregnancy complications, ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The pivotal stage of atherogenesis is antigen presentation by macrophages to T lymphocytes. This antigen could be a fragment of oxidized LDL"digested" by macrophage, heat shock protein 60, β2 glycoprotein I, or fragments of bacterial antigens. During interaction between these cells, an immunological response of type T helper 1 (cellular) or T helper 2 (humoral) arises. Th1 response and its mediators: (IFN-γ, TNF-α, interleukin 1, interleukin 12, and interleukin 18) increase atherogenesis, whereas Th2 response and its mediators: (interleukin 4, interleukin 5, and interleukin 10) decrease the development of atherosclerosis. The concept of atherosclerosis as an inflammatory disease is quite fresh; however, it is already considered an undisputable achievement of science, bringing particular therapeutic consequences ...
Expression of APOH (B2G1, BG) in soft tissue 1 tissue. Antibody staining with HPA001654, HPA003732 and CAB022214 in immunohistochemistry.
Mouse Monoclonal Anti-beta II Tubulin A Antibody (TU-13) [DyLight 680]. Validated: WB, ICC/IF, IHC, IHC-Fr. Tested Reactivity: Human, Mouse, Porcine, and more. 100% Guaranteed.
beta Tubulin I antibody [SAP.4G5] (tubulin beta class I) for ELISA, ICC/IF, IHC-P, IP, WB. Anti-beta Tubulin I mAb (GTX11312) is tested in Human, Mouse, Chicken, Dog, Rat, Hamster, Xenopus laevis, Bovine samples. 100% Ab-Assurance.
Mouse monoclonal DNA Ligase I antibody [1A9] validated for WB, ELISA and tested in Human. Referenced in 1 publication and 1 independent review. Immunogen…
Rabbit polyclonal Cryptochrome I antibody validated for WB, IHC, ICC and tested in Human and Mouse. With 1 independent review. Immunogen corresponding to…
beta 2 Defensin antibody (defensin, beta 4A) for ELISA, WB. Anti-beta 2 Defensin pAb (GTX59679) is tested in Human samples. 100% Ab-Assurance.
beta III Tubulin小鼠单克隆抗体(ab119100)可与人样本反应并经WB, IHC, ICC实验严格验证。所有产品均提供质保服务,中国75%以上现货。
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
TY - JOUR. T1 - IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. AU - Kelchtermans, H.. AU - Pelkmans, L.. AU - de Laat, B.. AU - Devreese, K. M.. PY - 2016/8. Y1 - 2016/8. KW - anti-cardiolipin. KW - anti-phospholipid antibody. KW - antiphospholipid syndrome. KW - (2)-glycoprotein I. KW - IgM. U2 - 10.1111/jth.13379. DO - 10.1111/jth.13379. M3 - Article. VL - 14. SP - 1530. EP - 1548. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and Haemostasis. SN - 1538-7933. IS - 8. ER - ...
Discover Antiphospholipid Syndrome Awareness T-Shirt from antiphospholipid syndrome, a custom product made just for you by Teespring. With world-class production and customer support, your satisfaction is guaranteed.
This case may be coincidental or it may be that the plasminogen deficiency increased the thrombotic tendency of APS in this patient. , 1996). Biochemistry. 35(43), 1383313842. 3 Genetics of Antiphospholipid Syndrome Jesús Castro-Marrero, Eva Balada, Josep Ordi-Ros and Miquel Vilardell-Tarrés Systemic Autoimmune Diseases Research Unit, Vall dHebron University Hospital Research Institute Universitat Autónoma de Barcelona, Barcelona Spain 1. , 2006). The etiology of APS, however, is still unknown. pdf in Orphanet, INSERM MIM nº 107320). APS can involve almost any organ system, including a wide range of clinical manifestations. , 2008). 2011) Microparticles in hemostasis and thrombosis. Circ Res. 108(10), 1284-1297. Pangburn MK & Rawal N. (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans. 30(Pt 6), 1006-1010. Pennings MT, van Lummel M, Derksen RH, Urbanus RT, Romijn RA, Lenting PJ & de Groot PG. (2006) Interaction of beta2-glycoprotein I with members of the ...
The Antiphospholipid Syndrome (APS) is characterized by thrombosis and pregnancy loss, clinical events mediated by pathogenic anti-phospholipid autoantibodies (aPL). β2-glycoprotein I (β2GPI) is the major autoantigens recognized by aPL. β2GPI is a cationic protein that binds to negatively charged surfaces such as those of apoptotic cells. This feature may lead to two major events: i) immunization with β2GPI fosters the Fc-receptor-mediated uptake by antigen presenting cells of apoptotic material decorated with β2GPIand the activation ofβ2GPI-specific T cells which in turn provide help to β2GPI-specific B cells for the production of anti-β2GPI; ii) apoptotic bodies decorated with β2GPI can be opsonized by anti-β2GPI and shifted towards a pro-inflammatory clearance by macrophages; epitope spread can occur with the generation of autoimmunity against nuclear autoantigens. In the presence of a predisposing genetic background and of a particular cytokine environment (type I interferons), the ...
Antiphospholipid syndrome is a systemic autoimmune disorder. It is usually defined as the clinical complex of vascular occlusion and ischaemic events occurring in patients who have circulating antiphospholipid antibodies. Pathology Patients hav...
Antibodies directed toward phosphatidylethanolamine (anti-PE) appear to occur particularly frequently in women with unexplained early fetal loss (UFL). Two studies have shown that the presence of anti-PE antibodies is a higher independent risk factor for early UFL than either aCL or anti-β2GPI antibodies.22,23 Moreover, anti-PE antibodies have been reported as the only aPL antibodies found in cases of UFL (73%). Regarding thrombosis, which is the other main clinical feature of APS, a multicenter study conducted within the framework of the European Forum on aPL antibodies found the prevalence of anti-PE was 15% in patients with unexplained venous thrombosis; this specificity was found mainly as the sole aPL antibody.24 At present, there is no accepted standardized method for the measurement of anti-PE, and the heterogeneity of these antibodies increases the difficulties in attaining such a goal. This problem significantly limits the utility of this assay. Hence, following current evidence, the ...
The classical clinical picture of the antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid...
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it compare to warfarin?
Hi, I have often thromboses, so Im taking anticoagulants regularly. Doctors are having trouble diagnosing. Maybe I have antiphospholipid syndrome.
... - also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids.
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) Rheumatology on CenterWatch
For decades, scientists and clinicians have been puzzled by an autoimmune condition, antiphospholipid syndrome (APS), which causes devastating health problems including uncontrolled blood clots and repeated pregnancy loss. Recent studies have shown that naturally produced antibodies that bind to phosphatidylethanolamine (PE) are positively correlated to antiphospholipid syndrome.. Phosphatidylethanolamine (PE), a lipid that makes up 20% of the inner cell membrane, has roles in membrane trafficking and reorganization. Paradoxically, the antibodies that bind to PE (anti-PE antibodies) in APS patients are produced outside of cells. This raises the question of how do the anti-PE antibodies bind to PE without having access to their targets? To unravel this mystery, Chemistry of Life Processes Institute faculty member and Northwestern Medicine investigator Ming Zhao (cardiology) synthesized special molecular probes to investigate the dynamic distribution of PE in living cells under the microscope. The ...
Expression of APOH (B2G1, BG) in testis tissue. Antibody staining with HPA001654, HPA003732 and CAB022214 in immunohistochemistry.
Glucose-6-phosphate isomerase antibody to detect human Glucose-6-phosphate isomerase . Validated on up to 12 cell lysates for western blotting. Try a trial size today.
APS may contribute to an increased frequency of stroke or MI, especially in younger individuals. Strokes may develop secondary to in situ thrombosis or embolization that originates from the valvular l... more
Principal Investigator:TSUTSUMI Akito, Project Period (FY):1997 - 1999, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:内科学一般
Cancer Therapy Advisor provides obsteticians and gynecologists with the latest information to correctly diagnose obgyn conditions, recommend procedures and guides. Visit often for updates and new information.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
In our study, linear hyperintensity along the medial margin of the GPi on T2WI was frequently observed in patients with MJD, which is consistent with the results of a previous report2 in which hyperintensity along the GPi was considered to indicate the degeneration of the lenticular fasciculus, which originates from the inner portion of the GPi and runs dorsomedially through the fibers of the internal capsule.5,6 The GPi and its efferent fibers, such as the lenticular fasciculus and ansa lenticularis, are frequently degenerated in patients with MJD, and there is also frequent involvement of the nigrostriatal and subthalamopallidal connections,1,7 which also run along the GPi.8,9 Thus, linear T2 hyperintensity in patients with MJD might reflect not only degeneration of the lenticular fasciculus, but also degeneration of other fibers near the GPi.. Control subjects older than 60 years had more frequent linear hyperintensity along the GPi than control subjects younger than 60 years. Thus, we ...
Mouse Monoclonal Anti-MHC Class I Antibody (F21-2) [DyLight 488]. Validated: WB, Flow, IHC, IHC-Fr. Tested Reactivity: Avian, Chicken, Turkey. 100% Guaranteed.
引用Abcams Anti-beta subunit Cholera Toxin抗体(ab34992)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
Complete information for GRID2IP gene (Protein Coding), Grid2 Interacting Protein, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
1997-2006 Healthboard.com. Healthboard.com is a purely informational website, and should not be used as a substitute for professional legal, medical or technical advice. ...
Antiphospholipid antibody syndrome: Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. 640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and use Aspirin, Hydroxychloroquine, Warfarin, Enoxaparin, and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms.
Antiphospholipid antibodies occur in various clinical states, including the primary antiphospholipid syndrome. Clinical features in these conditions appear to be caused by vasculopathy associated with the presence of these antibodies.. We report the case of a patient with primary antiphospholipid syndrome who experienced cardiac necrosis secondary to myocardial microvasculopathy in the absence of vasculitis. This case demonstrates unequivocally that noninflammatory myocardial microvasculopathy occurs in the primary antiphospholipid syndrome per se without any clinical or immunologic signs of systemic lupus erythematosus or other disease process. The histopathologic findings in the skin and myocardial biopsies showed a noninflammatory vasculopathy characterized by bland thrombi and lack of infiltration of the vessel wall by inflammatory cells. Ultrastructural examination of the myocardial biopsy confirmed the vascular thrombosis and endothelial activation and showed no deposits in basement ...
Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. Like many autoimmune diseases, it is more common in women than in men. The exact cause is not known, but activation of the system of coagulation is evident. Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with thrombosis and vascular disease. The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. Anti-ApoH and a subset of anti-cardiolipin antibodies bind to ApoH, which in turn inhibits Protein C, a glycoprotein with regulatory function upon the common pathway of coagulation (by degradating activated factor V). Lupus anticoagulant (LAC) antibodies bind to prothrombin, thus increasing its cleavage to thrombin, its active ...
OBJECTIVE To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. DESIGN Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 22 months. SETTING University-based tertiary medical center. PATIENTS Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. MEASUREMENTS AND MAIN RESULTS Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valvular involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with
Donadini, MP, Crowther, M. "Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations". Hematol-Oncol. vol. 24. 2010. pp. 669-76. (Recent concise review and update of this syndrome. Many of the clinical statistics were cited from this review.). Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. "Antiphospholipid syndrome". Lancet. vol. 376. 2010. pp. 1498-1509. (Along with the first listed reference, a key source for this chapter, especially with respect to treatment recommendations.). Frances, C. "Dermatological manifestations of Hughes antiphospholipid antibody syndrome". Lupus. vol. 19. 2010. pp. 1071-77. (Current review of cutaneous manifestations.). Weinstein, S, Piette, W. "Cutaneous manifestations of antiphospholipid antibody syndrome". Hematol Oncol Clinics N Am. vol. 22. 2008. pp. 67-77. (Relatively recent review of cutaneous findings.). Hughes, GRV. "Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics". Lupus. vol. 19. 2010. pp. ...
Hepatitis C, a worldwide viral infection, is an important health problem in Brazil. The virus causes chronic infection, provoking B lymphocyte dysfunction, as represented by cryoglobulinemia, non-organ-specific autoantibody production, and non-Hodgkins lymphoma. The aim of this research was to screen for the presence of antiphospholipid autoantibodies in 109 Brazilian hepatitis C virus carriers without clinical history of antiphospholipid syndrome. Forty healthy individuals were used as the control group. IgA, IgG, and IgM antibodies against cardiolipin and β2-glycoprotein I were measured with an enzyme-linked immunosorbent assay, using a cut-off point of either 20 UPL or 20 SBU. While 24 (22.0%) hepatitis C carriers had moderate titers of IgM anticardiolipin antibodies (median, 22.5 MPL; 95%CI: 21.5-25.4 MPL), only three carriers (,3%) had IgG anticardiolipin antibodies (median, 23 GPL; 95%CI: 20.5-25.5 GPL). Furthermore, IgA anticardiolipin antibodies were not detected in these individuals. ...
Antiphospholipid antibody syndrome is a fascinatingly complex disorder. It is an autoimmune disease, whereby the immune system attacks our own tissues. This article summarises the basic mechanisms of the condition and main diseases it is involved in. Learn about the diverse effects antiphospholipid antibody syndrome (APS) can have, from heart attack to miscarriage and how APS can be treated.
Antiphospholipid Antibody Syndrome (APS) is a highly prevalent cause of antibody-mediated thrombosis manifesting in venous thrombosis (DVT and PE), arterial thrombosis (most commonly stroke), and pregnancy complications. The diagnosis of definite APS requires both clinical and laboratory criterion as established by the working group of the International Congress on Antiphospholipid Antibodies (based on expert opinion). Since thrombosis and pregnancy loss are common in the general population, and antiphospholipid antibodies (aPL) occurs in a small percentage of the healthy public, it is important to demonstrate antibody persistence in patients who have the proper clinical indications in order to avoid misdiagnosis. Unfortunately, laboratory testing in this area lacks standardization, resulting in wide inter-laboratory variance. However, due to the commercialization of tests and automation, inter-laboratory variance has improved. Data on several new non-criterion tests suggest that they may ...
BACKGROUND Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis (arterial or venous) and/or pregnancy complications associated with the occurrence of autoantibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and/or anti-β2 glycoprotein-I antibodies confirmed at least twice over a 12 week period according to the 2006 Sydney criteria. Antiphospholipid antibodies are encountered in the general population with a reported prevalence of 1% to 5% However, APS is far more infrequent with a prevalence of 40-50/100,000 persons and an incidence of about 5 new patients/100,000 persons. APS can be diagnosed in patients with no apparent clinical or laboratory pathology (primary APS) or it may be related to numerous other conditions, autoimmune diseases (usually systemic lupus erythematosus), malignancies, infections and drugs (secondary APS). Women are at risk for APS since the disease is encountered in both the primary and the secondary state
This guideline reviews the features of the Antiphospholipid syndrome [APS]- definition, clinical association, pathophysiology and the laboratory detection of Antiphospholipid antibodies. It includes a section on who should be tested for aPL antibodies and how this should influence their management. It also includes sections on the management of APS and the Catastrophic Antiphospholipid syndrome [CAPS].. ...
NorthShore encourages patients to utilize our medical library. Read our Antiphospholipid antibody syndrome encyclopedia resources online.
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal ...
The antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPA) associated with thrombosis (arterial and venous) and pregnancy morbidity. This thesis has aimed to investigate the frequency of protein C pathway defects in patients with aPA and to study clinical correlates examine the mechanisms of antiphospholipid interference in the protein C pathway and to assess activated protein C (APC) resistance in patients with aPA in terms of thrombin generation. Although have I have discovered a high degree of heterogeneity in the phenotype of patients with APS, I have demonstrated APC resistance and increased thrombin generation in the majority of patients with APS. While in some cases, APC resistance is clearly immunoglobulin mediated, it is a multifactorial phenomenon with many confounding variables. My data suggest that immunoglobulin dependent APC resistance may occur through P2 glycoprotein-I dependent and independent mechanisms. In a detailed study of ...
Rationale: Antiphospholipid syndrome (APS) in pregnancy may trigger the life-threatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an additional treatment option. Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab due to high risk of developing devastating APS-related complications. The complement inhibitory effects of the treatment were examined both in the patient and the premature infant. Outcomes: Complement activity in the mother recovered considerably faster than anticipated; however, no new thrombosis or CAPS developed during the last week of pregnancy or postpartum. Blood sampling from the umbilical vein and artery, and from the infant after delivery showed low complement activity; however, only 0.3% of the eculizumab concentration detected in the mother, consistent with low placental passage of eculizumab. ...
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder in which patients have autoantibodies to phospholipid-bound proteins (eg, beta2-glycoprotein I, prothrombin, annexin A5). The pathophysiology is not precisely known. Antiphospholipid Syndrome (APS) is an important recognised cause of acquired treatable thrombophilia. It is characterised by the core clinical manifestations of thrombosis in both venous and arterial circulation resulting in recurrent thrombotic […]. ...
Outcome of primary antiphospholipid syndrome in childhood. Gattorno, M.; Falcini, F.; Ravelli, A.; Zulian, F.; Buoncompagni, A.; Martini, G.; Resti, M.; Picco, P.; Martini, A. // Lupus;2003, Vol. 12 Issue 6, p449 The objective of this paper is to investigate the long-term outcome of primary antiphospholipid syndrome (APS) in the paediatric age. The features of unselected patients with primary APS who had disease onset before the age of 16 years were retrospectively analysed in three Italian referral... ...
A look at antiphospholipid antibody syndrome, what laboratory tests can support the diagnosis of this syndrome, what are the causes and how is it treated. ...
Erkan: Antiphospholipid Syndrome patients with vascular events generally receive life-long anticoagulation, despite the lack of high-quality data on the risk of recurrence and optimal duration of anticoagulation. Given that at least 50% of thrombotic events in aPL-positive patients have recognizable triggers, the possibility of discontinuing anticoagulation in highly selected patients exists, especially when the triggers are eliminated. However, discontinuation of anticoagulation is a critical decision that requires careful assessment of comorbidities, triggers, and residual thrombosis as well as patient education. The 13th International Congress on aPL Treatment Task Force recommended that "in cases of first venous event, low-risk aPL profile, and a known transient precipitating factor, anticoagulation could be limited to 3-6 months." Given the importance of this question, i.e., anticoagulation withdrawal in APS, the development of a multicenter clinical trial protocol to determine whether ...
An examination of the symptoms, rupture of blood cells (fibrin production), liver damage, clotting (low serum heparin), high blood pressure (capillary apoptosis), proteinuria (low heparan sulfate (HS) to prevent protein loss), pointed to some obvious treatments and the causes. Infertility is often treated by in vitro fertilization/insemination, supported with aspirin and heparin injections to maintain gestation. These treatments are consistent with high levels of chronic inflammation that block implantation and stimulate labor. Infertility is also associated with antiphospholipid antibodies. A closer look at the antiphospholipid antibodies showed that they were directed against β2-glycoprotein-I. So, I expected the β2-glycoprotein-I protein to be the original target for the antibodies, the initiating antigen, but when I looked up the sequence of that protein, it lacked the expected basic triplet I have found in all other autoantigens and allergens. This meant to me that there was a different ...
In those with APS, the immune system fails to recognize certain blood proteins, attacking and destroying them as if they were bacteria or viruses. The destruction of these cells causes blood clots to form which can occur anywhere in the body. These clots can cause serious damage to cells and tissue depending on where they form and can break free, traveling anywhere in the body through the circulatory system. APS can also cause several complications during pregnancy. Though it is possible to have APS alone, a condition known as primary APS, many with the condition also suffer from rheumatic diseases such as lupus. When APS accompanies other disorders, it is known as secondary APS. Anyone can be affected by APS, but the disease is much more likely to affect women, with between 75 and 95 percent of those with APS being female. A higher incidence of APS is reported among African-American and Hispanic populations as well, although the reasons for this are unknown. The disorder has been recorded in ...
Introduction The aim of this study was to examine the prevalence and functional effects of antibodies directed against Factor (F)Xa and other serine proteases (SP) in patients with antiphospholipid...
The teams ongoing work may have far-reaching implications, including new ways to treat tissue damaged during a heart attack or stroke, and even a possible cure for cancer.. U.S. Patent No. 8,895,502, "B2-Glycoprotein I Peptide Inhibitors," was issued recently to the Kansas State University Research Foundation, a nonprofit corporation responsible for managing technology transfer activities at the university.. Sherry Fleming, associate professor of biology in the College of Arts & Sciences, said therapeutic peptides - or chains of amino acids - developed at Kansas State University can reduce or prevent the damage caused to intestinal tissue when blood and oxygen are restricted, called ischemia.. The peptides also are proving useful when blood flow returns to the affected tissue, called reperfusion, which usually is more damaging than ischemia.. "When cells are ischemic, they put out a novel molecular marker on their surface," Fleming said.. The markers, in effect, are the cells way of telling ...
New York - Motivated by the lack of treatment options for patients with antiphospholipid syndrome (APS), rheumatology researchers convened an international committee to address the problem directly. Their creation, APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking), is bringing together some of the foremost experts on APS-a little-known blood condition that can cause severe health consequences-to design clinical trials and registries focused on improving patient outcomes.. As a result of its first-ever meeting this past November, APS ACTION determined that distinct variations of APS-which causes frequent abnormal blood clots in arteries and veins -made patient studies into the condition very challenging. Blood clots form because the immune system mistakenly produces antibodies against phospholipid-binding plasma proteins, which puts those affected at risk for stroke and pregnancy complications.. "We concluded there are few controlled clinical trials ...
PMID 19740902] Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population [PMID 19644876] Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome [PMID 19796918 ...
This disease can have serious effects in pregnancy, both for the mother and the baby. These include strokes, blood clots, and recurrent miscarriage.
Schmeding and Schneider [57] reviewed the literature from 2000-2010 on the QOL of patients with SLE. It has been shown to lower QOL in patients with SLE vs. patients with other chronic diseases. SLE significantly reduces patients ability to cope with everyday activities. It is conditioned by age, fatigue and coexistence of neurological and psychiatric disorders, depression and irritability. There was no direct correlation between the degree of disease activity and organ damage in SLE and QOL.. Choi et al. [58] evaluated that the QOL of patients with SLE was lower than the control group, consisting healthy people. Reduced QOL resulted in depression, taking GCS and fatigue, which was not the result of the degree of disease activity and organ damage. Understanding psychological problems and appropriate treatment can help to improve the QOL of patients with SLE, especially those taking high doses of glucocorticosteroids, even if the disease activity is low. The study included 108 patients with SLE, ...
Is there anyone in here with a child who has Antiphospholipid Antibody Syndrome? My daughter was diagnosed at age 10. Now shes almost 12. It would just be nice...
Order monoclonal and polyclonal Annexin A13 antibodies for many applications. Selected quality suppliers for anti-Annexin A13 antibodies.
Sindroma Antiphospholipid (APS) - eshte nje semundje autoimmune karakterizuar nga perpunimin e sasive te medha te antitrupave me fosfolipide - strukturat kimike të cilat janë ndërtuar të qelizave...
As part of my job I have student nurses ( third year students) shadow me for 6 weeks at a time. My new student arrived Tuesday full of enthusiasm to met all my newborn clients and their families as she plans to finish her nursing degree and then move into midwifery.She was chatty and told me all about her life here as she had relocated to attend school nearby. She said the hardest part had been finding a doctor who understood her I pushed a bit further and found that at 21 she had psoratic arthritis, anti-phospholipid syndrome, raynauds and is currently suspecting lupus . Her mother has Sjogrens and RA. I really admired her just pushing forward with her dreams, not looking too far ahead in terms of where her illnesses might restrict her and enjoying all life had to offer ...
Im doing some researching for myself and came across some info that tweaked my interest. I have APS (antiphospholipid syndrome). APS presents very similar symptoms to MS. In fact, on an MRI the lesions are the same. A lot of people have been misdiagnosed with MS, when they actually have APS ...
97,. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihile E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group. .Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-27 267). Cerca con Google ...
Mycoplasma penetrans, a rare bacterium so far only found in HIV-infected persons, was isolated in the blood and throat of a non-HIV-infected patient with primary antiphospholipid syndrome (whose etiology and pathogenesis are unknown).
Scully, M., Thomas, M., Underwood, M., Watson, H., Langley, K., Camilleri, R., Clark, A., Creagh, D., Rayment, R., McDonald, V., Roy, A., Evans, G., McGuckin, S., Ni Ainle, F., Maclean, R., Lester, W., Nash, M., Scott, R. and O Brien P; collaborators of the UK TTP Registry 2014. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 124 (2), pp. 211-219. doi:10.1182/blood-2014-02-553131 A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom ...
You may also need to take blood thinners for 3 to 4 weeks after surgery to lower your risk of blood clots.. ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS) In general, you will need long-term treatment with a blood thinner for a long time if you have the APS. Initial treatment may be heparin, either unfractionated or low-molecular heparin. These medicines are given by injection.. In most cases, warfarin (Coumadin), which is given by mouth, is then started. It is necessary to monitor the level of anticoagulation frequently. This is most often done using the INR test.. If you have APS and become pregnant, you will need to be followed closely by a provider expert in this condition. You will not take warfarin during pregnancy, but will be given low-molecular weight heparin instead.. If you have SLE and APS your provider will also recommend that you take hydroxychloroquine. ...
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
Women with antiphospholipid antibodies (aPL) are at risk of adverse pregnancy outcomes, including recurrent first-trimester pregnancy loss and late pregnancy complications such as preeclampsia, HELLP (hemolysis, elevated liver enzyme levels, and low platelet levels) syndrome, premature delivery, intrauterine growth restriction, placental abruption, and intrauterine death. Current standard care in obstetric antiphospholipid syndrome includes aspirin and heparin and has resulted in live-birth rates of approximately 70%. However, 30% continue to have pregnancy complications. Hydroxychloroquine (HCQ) is suggested as a new treatment approach, but no randomized controlled trials (RCTs) have assessed its efficacy. This study aims to assess pregnancy outcome in women with aPL treated with HCQ versus placebo in addition to standard treatment. The HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) study is a phase IV multicenter RCT, in which pregnant women ...
To the Editor: Misra and colleagues (1) reported an increased incidence of anticardiolipin antibodies in patients with infectious mononucleosis and postulated the existence of cross-reactions between infectious (viral) antigens and cardiolipin. We report here our experience concerning immunologic and biochemical similarities between Pneumocystis carinii organisms and cardiolipin. We observed that in the acquired immunodeficiency syndrome (AIDS), anticardiolipin antibodies occurred almost exclusively among those patients who had active P. carinii pneumonia (2). To test the cross-reactive hypothesis, we did several experiments.. In the first set of experiments, rabbits were immunized with an antigen from P. carinii in Freunds adjuvant prepared according ...
Streydio C, Lacka K, Swillens S, Vassart G (Jul 1988). "The human pregnancy-specific beta 1-glycoprotein (PS beta G) and the ... Pregnancy-specific beta-1-glycoprotein 2 is a protein that in humans is encoded by the PSG2 gene. GRCh38: Ensembl release 89: ... "Entrez Gene: PSG2 pregnancy specific beta-1-glycoprotein 2". Thompson J, Koumari R, Wagner K, Barnert S, Schleussner C, Schrewe ... "Linkage of two human pregnancy-specific beta 1-glycoprotein genes: one is associated with hydatidiform mole". Proceedings of ...
Vertebrate beta-IG-H3. Vertebrate osteoblast-specific factor 2 (OSF-2). Mammalian NEU1/NG3 proteins. Drosophila midline ... Proteins known to contain an EMI domain include: Vertebrate Emilins, extracellular matrix glycoproteins. Vertebrate Multimerins ... extracellular matrix glycoproteins. Vertebrate Emu proteins, which could interact with several different extracellular matrix ... 484 (2): 164-8. doi:10.1016/S0014-5793(00)02140-2. PMID 11068053. Callebaut I, Mignotte V, Souchet M, Mornon JP (January 2003 ...
"Entrez Gene: MGAT2 mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase". Cormier-Daire V, Amiel J, ... Mutations in this gene may lead to carbohydrate-deficient glycoprotein syndrome, type II. The coding region of this gene is ... 1996). "Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of ... Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase is an enzyme that in humans is encoded by the MGAT2 gene ...
"Entrez Gene: MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase". Kumar R, Yang J, Eddy RL, et ... Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase is an enzyme that in humans is encoded by the MGAT1 gene ... 2007). "Refolding of human beta-1-2 GlcNAc transferase (GnT1) and the role of its unpaired Cys 121". Biochem. Biophys. Res. ... UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I is a medial-Golgi enzyme essential for ...
1996). "Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of ... This gene encodes a microsomal beta-glucosidase that catalyzes the hydrolysis of bile acid 3-O-glucosides as endogenous ... "Entrez Gene: GBA2 glucosidase, beta (bile acid) 2". Land A, Braakman I (2001). "Folding of the human immunodeficiency virus ... Matern H, Heinemann H, Legler G, Matern S (1997). "Purification and characterization of a microsomal bile acid beta-glucosidase ...
2001). "Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation". Int. J. Cancer. ... The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions ... Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT (January 2001). "Glycoprotein 90K/MAC-2BP interacts with ... Putative ligands for a cytosolic beta-galactoside lectin". J. Biol. Chem. 266 (28): 18731-6. PMID 1917996. Yu B, Wright SD ( ...
... (Gal-3) is also a member of the beta-galactoside-binding protein family that plays an important role in cell-cell ... Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT (January 2001). "Glycoprotein 90K/MAC-2BP interacts with ... Galectin-3 has an affinity for beta-galactosides and exhibits antimicrobial activity against bacteria and fungi. This protein ... Putative ligands for a cytosolic beta-galactoside lectin". The Journal of Biological Chemistry. 266 (28): 18731-6. PMID 1917996 ...
... (Apo-H), previously known as β2-glycoprotein I and beta-2 glycoprotein I, is a 38 kDa multifunctional ... This protein domain is composed of four well-defined anti-parallel beta-strands and two short alpha-helices, as well as a long ... Schousboe I (1985). "beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation ... Nimpf J, Wurm H, Kostner GM (1987). "Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP- ...
Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y (2000). "T cells that are autoreactive to beta2-glycoprotein I ... 1996). "Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus". ... 1997). "Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI ... Viard JP, Amoura Z, Bach JF (1991). "[Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of ...
Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (August 1987). "Lp(a) glycoprotein phenotypes. Inheritance and ... Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC (1994). "Activation of transforming growth factor-beta is inhibited in ... Köchl S, Fresser F, Lobentanz E, Baier G, Utermann G (1997). "Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I ... Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation". Hum. Genet. 82 (1): 73-8. doi:10.1007/BF00288277. ...
Viard JP, Amoura Z, Bach JF (1991). "[Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of ... 2): CD002859. doi:10.1002/14651858.CD002859.pub2. PMID 15846641. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H (2006 ...
Sodium channel subunit beta-2 is a protein that in humans is encoded by the SCN2B gene. Sodium channel GRCh38: Ensembl release ... a transmembrane glycoprotein with a CAM motif". Cell. 83 (3): 433-42. doi:10.1016/0092-8674(95)90121-3. PMID 8521473. Eubanks J ... "Entrez Gene: SCN2B sodium channel, voltage-gated, type II, beta". Hartshorne RP, Catterall WA (1984). "The sodium channel from ... 1996). "Structure and function of the beta 2 subunit of brain sodium channels, ...
Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG (2003). "Dimers of beta 2-glycoprotein I increase ... It is caused by the presence of antibodies against anionic phospholipids and β2-glycoprotein I (β2GPI). The anti-β2GPI ... The presence of amyloid beta (Aβ) protein deposits in neuronal extracellular space is one of the hallmarks of Alzheimer's ... PI3K activation leads to inhibitory phosphorylation of the tau kinase glycogen synthase kinase 3 beta (GSK3B), which alters the ...
Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA (1992). "A phospholipid-beta 2-glycoprotein I complex is an antigen for ... Kumar KS, Jyothy A, Prakash MS, Rani HS, Reddy PP (2002). "Beta2-glycoprotein I dependent anticardiolipin antibodies and lupus ... The syphilis anti-cardiolipin antibodies are beta-2 glycoprotein independent, whereas those that occur in the antiphospholipid ... are beta-2 glycoprotein dependent, and this can be used to tell them apart in an ELISA assay. This test is very useful as the ...
Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa". The Journal of Biological ... Henry ML, Everson B, Ratnoff OD (May 1988). "Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein ... Fujikawa K, McMullen BA (Sep 1983). "Amino acid sequence of human beta-factor XIIa". The Journal of Biological Chemistry. 258 ( ... 29 (2): 229-52. doi:10.1016/j.cll.2009.04.002. PMID 19665676. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, ...
This gene is one of seven beta-1,4-galactosyltransferase (beta4GalT) genes. They encode type II membrane-bound glycoproteins ... Beta-1,4-galactosyltransferase 2 is an enzyme that in humans is encoded by the B4GALT2 gene. ... Lo NW, Shaper JH, Pevsner J, Shaper NL (Aug 1998). "The expanding beta 4-galactosyltransferase gene family: messages from the ... Pal R, Hoke GM, Sarngadharan MG (1989). "Role of oligosaccharides in the processing and maturation of envelope glycoproteins of ...
HIV-1 envelope glycoprotein contains at least four sites for neutralizing antibodies. Among these sites, the membrane-proximal ... beta 2-glycoprotein I (apolipoprotein H)". Proc. Natl. Acad. Sci. U.S.A. 87 (11): 4120-4. doi:10.1073/pnas.87.11.4120. PMC ... 59 (2): 487-491. doi:10.1111/j.1471-4159.1992.tb09396.x. PMID 1629722. Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F ... 82 (2): 224-233. doi:10.1046/j.1471-4159.2002.00945.x. Keij JF, Bell-Prince C, Steinkamp JA (2000). "Staining of mitochondrial ...
IgG or IgA As β2-glycoprotein dependent or independent In autoimmune disease ACA are beta-2 glycoprotein dependent syphilis ACA ... β2-glycoprotein I has been identified as Apolipoprotein H and is required for the recognition of ACA in autoimmune disease. ... beta 2-glycoprotein I (apolipoprotein H)". Proc. Natl. Acad. Sci. U.S.A. 87 (11): 4120-4124. doi:10.1073/pnas.87.11.4120. PMC ... 2 (8361): 1211-1214. doi:10.1016/S0140-6736(83)91267-9. PMID 6139567. Harris EN, Gharavi AE, Loizou S, et al. (1985). " ...
"Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal ... A new type of beta-propeller architecture formed by oligomerization and interacting with fucoside, fucosyllactose, and plant ... α-D-Sia-(2-6)-β-D-Gal-(1-4)-Glc(NAc)[29], α-D-Sia-(2-6)-β-D-Gal(NAc) [22] získává se z kůru bezu; je specifický k α-D-Sia-(2-6 ... α-D-Gal-(1-3)(α-L-Fuc-(1-2)-Gal GNA Galanthus nivalis sněženka podsněžník nesubstituované α-D-Man-(1-3)[11] nerozponává ...
T-cell surface glycoprotein CD1e, membrane-associated is a protein that in humans is encoded by the CD1E gene. This gene ... proteins and form heterodimers with beta-2-microglobulin. The CD1 proteins mediate the presentation of primarily lipid and ... 19 (2): 285-92. doi:10.1002/eji.1830190211. PMID 2467814. Yu CY, Milstein C (1990). "A physical map linking the five CD1 human ... 54 (2): 122-7. doi:10.1034/j.1399-0039.1999.540202.x. PMID 10488738. Mirones I, Oteo M, Parra-Cuadrado JF, Martínez-Naves E ( ...
This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The beta ... The glycoprotein subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes a beta 3 subunit. A pseudogene ... Sodium/potassium-transporting ATPase subunit beta-3 is an enzyme that in humans is encoded by the ATP1B3 gene. ATP1B3 has also ... "Entrez Gene: ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide". Lingrel JB, Orlowski J, Shull MM, Price EM (1990). " ...
Hunt, J.E., McNeil, H.P., Morgan, G.J., Crameri, R.M., Krilis, S.A. "A phospholipid-beta 2-glycoprotein I complex is an antigen ... Hunt, J.E., Simpson, R.J., Krilis, S.A. "Identification of a region of β2-glycoprotein I critical for lipid binding and anti- ... Hunt, J., Krilis, S. "The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region ... β2-glycoprotein I (apolipoprotein H)" (1990) Proceedings of the National Academy of Sciences of the United States of America, ...
Harpaz N, Schachter H. Control of glycoprotein synthesis. Processing of asparagine-linked oligosaccharides by one or more rat ... alpha-D-mannoside beta 2-N-acetylglucosaminyltransferase I. J Biol Chem. 1980 May 25;255(10):4894-902. Williams D, Schachter H ... Schachter also helped characterize the first Carbohydrate-Deficient Glycoprotein Syndrome (CDG-IIa; now known as Congenital ... Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, ...
3 This enzyme is involved in the synthesis of glycoproteins. Harpaz N, Schachter H (May 1980). "Control of glycoprotein ... alpha-D-mannoside beta 2-N-acetylglucosaminyltransferase I". The Journal of Biological Chemistry. 255 (10): 4894-902. PMID ... Mannosidase II is the GlcNAcMAN5-cleaving enzyme in glycoprotein biosynthesis and mannosidases Ia and IB are the enzymes ...
The systematic name of this enzyme class is CMP-N-acetylneuraminate:beta-D-galactosyl-1,4-N-acetyl-D-glucosaminy l-glycoprotein ... 3-beta-D-galactosyl-1,4-N-acetyl-D- glucosaminyl-glycoprotein Thus, the two substrates of this enzyme are CMP-N- ... acetylneuraminate and beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-glycoprotein, whereas its 3 products are CMP, alpha-N- ... 3-beta-D-galactosyl-1,4-N-acetyl-D-, and glucosaminyl-glycoprotein. This enzyme belongs to the family of transferases, ...
Alpha 1 acid glycoprotein Alpha 1 fetoprotein alpha2-macroglobulin Gamma globulins Beta-2 microglobulin Haptoglobin ... 2 (3): 185-95. doi:10.1016/j.cels.2016.02.015. PMID 27135364. Clinical Chemistry : a laboratory perspective / [edited by] Wendy ...
"Enzymatic conversion of proteins to glycoproteins". Proc. Natl. Acad. Sci. U.S.A. 74 (1): 134-8. Bibcode:1977PNAS...74..134P ... 12 (2): 95-101. doi:10.1093/glycob/12.2.95. PMID 11886842.. *^ a b Knauer R, Lehle L (January 1999). "The ... The sugar Glc3Man9GlcNAc2 (where Glc=Glucose, Man=Mannose, and GlcNAc=N-acetylglucosamine) is attached to an asparagine (Asn) ... They are labelled "Type I" if the defective gene is for an enzyme involved in the assembly or transfer of the Glc3Man9GlcNAc2- ...
... xylosyltransferase Dolichyl-xylosyl-phosphate-protein xylosyltransferase Flavonol-3-O-glycoside xylosyltransferase Glycoprotein ... Xylosyltransferase are transferase enzymes which act upon xylose and are classified under EC 2.4.2. More specifically, they can ... 2-beta-D-xylosyltransferase Protein xylosyltransferase Xyloglucan 6-xylosyltransferase XYLT1 XYLT2 Zeatin O-beta-D- ...
1. Beta-2-glycoprotein 1. General function:. Involved in eukaryotic cell surface binding. Specific function:. Binds to various ... CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:0) contains one chain of (9Z,12Z-octadecadienoyl) at the C1 position, two chains of (9Z- ... CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:0) is a cardiolipin (CL). Cardiolipins are sometimes called double phospholipids because ... 2. Cardiolipin synthase. General function:. Involved in phosphotransferase activity, for other substituted phosphate groups. ...
... predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS ... predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS ... predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS ... On brain MRI, one or more white matter lesions are present; they are hyperintense on T2-weighted images and hypointense on T1- ...
... Enzyme-linked immunosorbent assay (ELISA) Send Out. ...
... beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl- (1->4)-N-acetyl-beta-D-glucosaminyl}asparagine The 5 substrates of this ... beta-D-man nosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glu cosaminyl}asparagine) 2-beta-D- ... beta-D-, mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-, and glucosaminyl}asparagine) 2-beta-D- ... beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-]], and [[(1->4)-N-acetyl-beta-D-glucosaminyl}asparagine]]. This enzyme ...
Beta 2 Glycoprotein I (β2GPI) is a plasma protein that binds to neoepitopes on damaged cells including anionic phospholipids ...
... beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-N-Asn-[protein] = UDP + beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-(alpha- ... D-Man-(1->6))-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-N-Asn-[protein]. ... UDP-N-acetyl-alpha-D-glucosamine + alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-(alpha-D-Man-(1->6))-alpha-D-Man-(1->6)]-beta-D-Man-( ... Glycoprotein. Proteomic databases. PaxDb, a database of protein abundance averages across all three domains of life ...
Please allow 2-3 weeks for delivery. Upon receipt of an order each kit is assembled and tested to ensure that it meets ...
aCL derived from either APS patients or (NZW x BXSB)F1 mice bound to beta 2-GPI coated on the irradiated plates, depending on ... Antibody binding to beta 2-GPI on the irradiated plates was competitively inhibited by simultaneous addition of cardiolipin (CL ... There was a high correlation between binding values of aCL in sera from 40 APS patients obtained by the anti-beta 2-GPI enzyme- ... Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase ...
Recently we determined that 3G4 recognizes PS through the formation of a complex with plasma protein beta-2-glycoprotein 1 ( ... Fusion proteins composed of mouse IgG2a Fc and mouse beta-2-glycoprotein 1 bind to endothelial cells with exposed ... Fusion proteins composed of mouse IgG2a Fc and mouse beta-2-glycoprotein 1 bind to endothelial cells with exposed ... Fusion proteins composed of mouse IgG2a Fc and mouse beta-2-glycoprotein 1 bind to endothelial cells with exposed ...
Beta 2 Glycoprotein 1 IgM ELISA kit. Our kits are FDA, CE and ISO certified. ... Quality Beta 2 Glycoprotein 1 IgG ELISA kit from ELISA kits manufacturer and elisa kits supplier: ... Beta 2 Glycoprotein 1 IgG ELISA kit. MPO (p-ANCA) ELISA kit. Sm ELISA kit. Anti CCP ELISA kit. Gliadin IgA ELISA kit. ... Beta 2 Glycoprotein 1 IgM ELISA kit. Name. Beta 2 Glycoprotein 1 IgM ELISA kit ...
What is beta 2 glycoprotein I? Meaning of beta 2 glycoprotein I medical term. What does beta 2 glycoprotein I mean? ... Looking for online definition of beta 2 glycoprotein I in the Medical Dictionary? beta 2 glycoprotein I explanation free. ... Beta 2 glycoprotein I ([[beta].sub.2]GPI) is a type of single-strand protein that contains five structural domains (DI-DV).. ... beta 2 glycoprotein I. β 2 glycoprotein I. major target antigen to which anticardiolipin antibodies bind. ...
Beta 2 Glycoprotein 1 IgM ELISA kit. Our kits are FDA, CE and ISO certified. ... Quality Beta 2 Glycoprotein 1 IgG ELISA kit from ELISA kits manufacturer and elisa kits supplier: ... Beta 2 Glycoprotein 1 IgG ELISA kit. Name. Beta 2 Glycoprotein 1 IgG ELISA Test ... Beta 2 Glycoprotein 1 IgG ELISA kit description:. The Diagnostic Automation Beta2GP1 IgG Enzyme-linked Immunosorbent Assay ( ...
Search results for Human Beta-2-glycoprotein 1 (APOH) ELISA Kit. Find and buy Antibodies, ELISA Kits or Research Products on ... 02015382585Human beta 2-Glycoprotein (ApoH) ELISA Kit[beta 2-Glycoprotein (ApoH)]Info MyBioSource MBS564182 NA0.00Ask ... 02014724774Human Beta-2-glycoprotein 1 (APOH) ELISA KitInfo abebio AE63189HU 1X plate of 96 wells572.96Ask ... 01014724774Human Beta-2-glycoprotein 1 (APOH) ELISA KitInfo abebio AE63189HU 1X plate of 48 wells423.64Ask ...
Beta-2-Glycoprotein 1, apolipoprotein H, is a cofactor in antiphospholipid antibody binding and is the critical antigen in the ... 36552: Beta-2-glycoprotein I (beta-2-gpi) Iga Autoantibodies [36552 Print View. ... Beta-2-Glycoprotein 1 Antibody is more specific than Cardiolipin Antibody that may express reactivity in patients with syphilis ...
The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation ... anti-beta-2-glycoprotein-I (anti-beta2GPI) and anti-prothrombin, on in vitro TF-induced thrombin generation in the presence and ... The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation , Haematologica, vol ... antiphospholipid antibodies, tissue factor pathway inhibitor, thrombin generation, b-2-glycoprotein-I.. ...
Autoimmune antibodies to beta(2)-glycoprotein I (beta2GPI) have been proposed to be clinically relevant because of their strong ... Impaired thrombin generation in beta 2-glycoprotein I null mice.. Sheng, Y; Reddel, SW; Herzog, H; Wang, YX; Brighton, T; ...
Apolipoprotein H (beta-2-glycoprotein I) polymorphism in Asians.. Authors: Saha, N. Kamboh, M.I.. Kelly, L.J.. Ferrell, R.E.. ... Saha, N.,Kamboh, M.I.,Kelly, L.J.,Ferrell, R.E.,Tay, J.S. (1992). Apolipoprotein H (beta-2-glycoprotein I) polymorphism in ...
3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Antibody at MyBioSource. Custom ELISA Kit, Recombinant Protein ... 3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase ELISA Kit, Recombinant Protein and Alpha-1, ... Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase. LOG IN MY ACCOUNT CART CONTENTS CHECKOUT ... Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase. Alpha-1,3-mannosyl-glycoprotein 2-beta-N- ...
Dr Lal PathLabs offers test service for Phospholipid Syndrome Panel With Beta 2 Glycoprotein 1 Ihr Test for checking Autoimmune ...
Beta-2-Glycoprotein-1 APOH Deficient Plasma. View Product. APOH-DP - Frozen Apoliporotein-H Deficient Plasma - 1ml or bulk ... Our Beta-2-Glycoprotein-1 APOH Deficient Plasma is for Research Use Only, flash frozen and available in 1ml vials or bulk ... Affinitys Beta-2-Glycoprotein-1 APOH Deficient Plasma is a normal human plasma where B2GP1 or APOH has been removed by ... Home / Deficient Plasma / Beta-2-Glycoprotein-1 APOH Deficient Plasma. Beta-2-Glycoprotein-1 APOH Deficient Plasma. ...
Apolipoprotein H has been implicated in a variety of physiologic pathways including lipoprotein metabolism, coagulation, and the production of antiphospholipid autoantibodies. APOH may be a required cofactor for anionic phospholipid binding by the antiphospholipid autoantibodies found in sera of many patients with lupus and primary antiphospholipid syndrome, but it does not seem to be required for the reactivity of antiphospholipid autoantibodies associated with infections. [provided by RefSeq, Jul 2008 ...
Tag: beta-2-glycoprotein-I. HPV, Tetanus Vaccine Causes New Disease: New Vaccines Worse?. by Heidi Stevenson ... Categories Adjuvants, HPV, Tetanus, VaccineTags antiphospholipid syndrome, APS, ASIA, Atherosclerosis, beta-2-glycoprotein-I, ... Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI, PNAS, G. Michael Iverson, ... β2 glycoprotein 1 (β2GPI), the major target in anti phospholipid syndrome (APS), is a special human complement regulator, Blood ...
Authority records BETA Bohlin, MariaBlomberg, Lars G Search in DiVA By author/editor. Bohlin, MariaBlomberg, Lars G By ... Human beta-2-glycoprotein I (b2gpI) is a phospholipid- and heparin-binding plasma glycoprotein involved in autoimmune diseases ... Capillary electrophoresis-based analysis of phospholipid- and glycosaminoglycan-binding by human beta-2-glycoprotein I. Bohlin ...
Presence of Anti Beta 2 Glycoprotein 1(Beta 2GP1) antibodies is an independent risk factor for thrombosis in autoimmune ...
Test ID BLOD1332 Beta 2 Glycoprotein I IgG Specimen Type/Requirements. Blue tob (Sodium Citrate) tube - Plasma (preferred). Red ... Beta-2-GPI autoantibodies are found in patients with antiphospholipid syndrome (APS) and are associated with increased risk of ... Beta-2 GPI autoantibodies are found only inpatients with autoimmune diseases, while cardiolipin autoantibodies can be ...
  • CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:0) is a cardiolipin (CL). (hmdb.ca)
  • Crystal structure of a ternary complex between human chorionic gonadotropin (hCG) and two Fv fragments specific for the alpha and beta-subunits. (ebi.ac.uk)
  • Recent evidence indicates that beta 2GPI exerts multiple inhibitory effects on the coagulation pathway and platelet aggregation. (edu.au)
  • CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:0) contains one chain of (9Z,12Z-octadecadienoyl) at the C1 position, two chains of (9Z-octadecenoyl) at the C2 and C3 positions, one chain of hexadecanoic acid at the C4 position fatty acids. (hmdb.ca)
  • Women carrying 1 of the 2 polymorphisms did not experience more thrombotic events than women who screened negative for thrombophilia. (bloodjournal.org)
  • Two splice variants of FXYD domain containing ion transport regulator 2 (FXYD2), a regulating subunit of the Na + -K + -ATPase, were identified as preferentially present in human pancreatic islets. (springer.com)